GlaxoSmithKline Pharmaceuticals Ltd on Tuesday reported a 9.45 per cent rise in consolidated net profit at Rs 164.56 crore in the third quarter ended December 31, 2022.
The company had posted a consolidated net profit of Rs 150.35 crore in the same quarter last fiscal, GlaxoSmithKline Pharmaceuticals (GSK Pharma) said in a regulatory filing.
Consolidated revenue from operations during the quarter under review stood at Rs 802.3 crore as against Rs 815.92 crore in the year-ago period, it added.
Total expenses were lower at Rs 590.1 crore compared to Rs 636.56 crore in the corresponding quarter last fiscal.
"General medicines portfolio grew by 10 per cent led by anti-infectives and dermatology therapies...Vaccine sales were down for the quarter in a declining self-pay vaccines market. However, we continue to gain market share for key vaccine brands," GSK Pharma Managing Director Bhushan Akshikar said.
During the quarter, he said, the National List of Essential Medicines (NLEM), 2022 was announced.
"The list includes 16 GSK brands, of which revised prices have been notified for eight brands. We will continue to drive various initiatives to mitigate the impact of the same," Akshikar said.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app